Find a Clinical Trial
|Protocol||Trial Name and Objective|
Phase I/II Study of Weekly Abraxane and RAD001 in Women with Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group
The purpose of this study is to determine what dose of RAD001and Abraxane is safe to use when the two drugs are used at the same time. Other goals in this study are to learn about the effect of RAD001 and Abraxane on tumor growth; to find out what amount of RAD001 is present in the blood when it is combined with Abraxane; and to learn more about certain genes that produce proteins that may help predict or show an effect (a response to treatment) of this drug combination. Phase I: To determine the maximum tolerated dose (MTD) of RAD001 in combination of weekly Abraxane and determine the Phase II dose of RAD001.Phase II: To determine the activity on tumors, of the combination of RAD001 and Abraxane at the Phase II dose in patients with advanced breast cancer.
NCI/CTEP 8282: A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
The main goal of this research study is to find out the highest and safest dose of the study drug, ABT-888, that can be given on a daily basis to subjects with the following cancers: a cancer with a BRCA 1 or 2 (breast cancer 1 or 2 gene) associated cancer (most often breast and ovarian, but may include prostate and pancreatic); ovarian, fallopian tube, or primary peritoneal cancer that returns within 6 months after responding to a platinum-based chemotherapy, or breast cancer that does not express estrogen receptor, progesterone receptor, or human epidermal growth factor receptor (referred to as triple-negative breast cancer). This study will test different dosages of ABT-888. The study uses a well-established process of slowly increasing drug dosage to determine the highest dosage that can be given without causing serious side effects. Other purposes of this research study will be to examine what side effects occur when the drug is given to subjects, how much ABT-888 is in the blood at specific times after it is received, and whether or not ABT-888 is effective in treating these specific types of cancer.
Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women with Breast Cancer: A Phase II Trial
This study is a non-randomized, single arm study of female patients with invasive carcinoma of the breast who have had (or will have) a mastectomy followed by radiation therapy. The term 'accelerated' means that a higher radiation dose per treatment will be delivered over a shorter period of time (compared to the standard). Prior studies suggest that the accelerated radiation scheme used in this study is comparable to the standard or conventional whole breast radiation. That is, the evidence points to accelerated treatments may work at least as well as the longer, standard treatments. Along with measuring the recurrence outcomes, we will be measuring treatment side effects and cosmesis (how well the study treatment plan preserves the appearance of your surgically reconstructed breast).
NCI/CTEP 8457: A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer
Primary: To determine if addition of bortezomib to fulvestrant improves median PFS compared with fulvestrant alone in postmenopausal women with ER-positive locally advanced inoperable or metastatic breast cancer who have disease that is resistant to aromatase inhibitor therapy
The BEACON Study (BREAST CANCER OUTCOMES WITH NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 vs Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane and Capecitabine
NSABP FB-9: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant NSABP Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer
Primary objective:To determine the pathologic complete response rate in breast and axillary lymph nodes for patients with HER2-negative locally advanced breast cancer following neoadjuvant therapy
M13-695: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects with Solid Tumors
Assess and compare the bioavailability of three test extended release (ER) formulations of veliparib with that of the current imemdiate release formulation of veliparib. Evaluate the potential effect of food on the oral bioavailability of three test extended release (ER) formulations of veliparib. Establish the maximum tolerated dose (MTD) and to establish the recommended Phase 2 dose (RPTD) and schedule for one or more of the ER formulations. Secondary objectives of the study are to assess the safety and tolerability of the ER formulations.
Safety and Feasibility of Short-course, Accelerated, Hypofractionated Partial Breast Radiotherapy in Women with Early Stage Breast Cancer Using the Contura MLB Breast Brachytherapy Catherer: A Phase II Trial
To determine whether the short course accelerated partial breast brachytherapy treatment schedules result in local control that is comparable to conventional fractionation schemes for APBI (10 fractions delivered bid over 5 days).
RTOG 1014: A Phase II study of repeat breast preserving surgery and 3D conformal partial breast re-irradiation (PBri) for local recurrence of breast cancer
The purpose of this study is to evaluate the tumor control and side effects of partial breast re-irradiation given after a lumpectomy. Patients who have had a lumpectomy and are eligible for this trial will receive highly conformal three dimensional conformal radiation therapy (3D-CRT) to treat only the area in the breast where the lumpectomy was performed. 3D-CRT tries to lower the amount of radiation that normal tissues receive, while still delivering the desired amount of radiation to the cancer and to areas that the study doctor thinks may have cancer cells.
Phase I Study of Pazopanib in Combination with Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients with Advanced Solid Tumors
1.1 Primary Objective(s)
LFA102: CLFA102X2102: A phase I, multicenter, open-label study of LFA102 administered intravenously in patients with prolactin receptor-positive castration-resistant prostate cancer or prolactin receptor-positive metastatic breast cancer
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Primary Obj. - to determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX. In patients with 1-3 positive nodes, and hormone receptor (HR)-positive, HER2-negative brest cancer with RS < or equal to 25 treated with endocrine therapy we will test whether the difference in disease-free survival for patients treated with chemo compared to no chemo depends directly on the magnitude of RS. If benefit depends on the RS score, the trial will determine the optimal cutpoint for recommending chemo or not.
NSABP FB-7: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib andor Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer
Primary aim and endpoint
A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Objectives: The primary objective of the study is to assess the progression-free survival (PFS) of oral
NSABP PROTOCOL B-49:A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-RiskNode-Negative, HER2-Negative Breast Cancer
Primary Aim: Aim: To determine if the docetaxel plus cyclophosphamide regimen is non-inferior to the anthracycline-based chemotherapy regimens in terms of invasive disease-free survival (IDFS) by combining B-49 data with the TAC and TC arms of NSABP B-46-I/USOR 07132 and the data from USOR 06-090.
Significance of Single Nucleotide Polymorphisms in Breast Cancer Patients Undergoing Radiation Therapy
In a cohort of approximately 250 women, diagnosed with breast cancer and treated with breast conserving surgery or mastectomy and radiation we will evaluate the frequency of this polymorphism (SNP309). We will correlate the polymorphism status with other clinical, pathologic and genetic information we have on these 250 women, including but not limited to stage, age of onset of disease, receptor status, her2 status, and the status of BRCA1 and BRCA2. We will recruit additional patients with a new diagnosis of breast cancer to correlate the status of SNP309 with other clinical and pathological variables.
Environmental Determinants of Puberty. A Pilot Study
To test the feasibility of conducting a cohort study of prepubertal girls in New Jersey and allow us to learn essential information for the planning of such future study.
THE WOMEN'S CIRCLE OF HEALTH STUDY
Effect of DNA Variations on Breast Cancer Risk and Recurrence. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
The purpose of this study is to collect, store and analyze deoxyribonucleic acid (DNA) from patients. Your genes are inherited from your parents and they are in part responsible for why you are different from other people. These slight differences in genes among people are called polymorphisms. By collecting DNA from patients with cancer and without, scientists will be able to study whether these polymorphisms are important in determining the occurrence of cancer and how patients respond to cancer treatments. For example, having a particular polymorphism in a gene may affect the type of side effects you may have from certain drugs during treatment compared to a person who does not have this polymorphism.
Life After Cancer: Examining Survivor Transitions from Specialist to Primary Care. A study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Aim 1: Explore the role of primary care providers in breast and prostate cancer survivors' cancer follow-up care.